What is HC Wainwright’s Estimate for DVAX Q2 Earnings?

Dynavax Technologies Co. (NASDAQ:DVAX) – Equities researchers at HC Wainwright issued their Q2 2025 earnings per share estimates for Dynavax Technologies in a note issued to investors on Tuesday, January 14th. HC Wainwright analyst E. White expects that the biopharmaceutical company will earn $0.08 per share for the quarter. HC Wainwright has a “Buy” rating and a $31.00 price objective on the stock. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.19 per share. HC Wainwright also issued estimates for Dynavax Technologies’ Q3 2025 earnings at $0.12 EPS, FY2025 earnings at $0.35 EPS and FY2026 earnings at $0.45 EPS.

Separately, StockNews.com raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday.

Dynavax Technologies Stock Down 0.7 %

DVAX stock opened at $12.39 on Thursday. Dynavax Technologies has a 1-year low of $9.74 and a 1-year high of $14.30. The business’s 50 day simple moving average is $12.78 and its 200 day simple moving average is $11.66. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $1.63 billion, a PE ratio of 95.32 and a beta of 1.34.

Institutional Investors Weigh In On Dynavax Technologies

A number of institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in Dynavax Technologies by 175.5% during the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 1,685 shares during the last quarter. US Bancorp DE increased its position in Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,034 shares during the period. Capital Performance Advisors LLP acquired a new stake in shares of Dynavax Technologies during the third quarter worth $45,000. Nisa Investment Advisors LLC lifted its holdings in shares of Dynavax Technologies by 44.6% during the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 1,679 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Dynavax Technologies in the third quarter valued at about $89,000. Institutional investors own 96.96% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.